UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of Dec, 2022
Commission File Number: 001-41106
Incannex Healthcare Limited
(Exact name of Registrant as specified in its charter)
not applicable
(Translation of Registrant’s name into English)
Australia
(Jurisdiction of incorporation or organization)
Joel Latham
Chief Executive Officer and Managing Director
Level
39, Rialto South Tower
525 Collins Street
Melbourne 3000
Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes ☐ No ☒
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes ☐ No ☒
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On December 01, 2022, Incannex Healthcare Limited filed with the Australian Securities Exchange an announcement captioned “Trading Halt”, a copy of which announcement is attached to this Form 6-K as Exhibit 99.1.
1
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Incannex Healthcare Limited | ||
| Date: December 01, 2022 | By: | /s/ Joel Latham |
| Name: | Joel Latham | |
| Title: | Chief Executive Officer and Managing Director | |
2
INDEX TO EXHIBITS
Exhibit No.
| 99.1 | ASX Announcement, dated December 01, 2022 – Trading Halt |
3
Exhibit 99.1
Market Announcement
1 December 2022
Incannex Healthcare Limited (ASX: IHL) – Trading Halt
Description
The securities of Incannex Healthcare Limited (‘IHL’) will be placed in trading halt at the request of IHL, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 5 December 2022 or when the announcement is released to the market.
Issued by
Melissa Kostopoulos
Compliance Adviser, Listings Compliance (Melbourne)
| 1 December 2022 | Market Announcement 1/1 |
| ASX Limited | ASX Customer Service Centre 131 279 | asx.com.au |
 |
Date: 1st December 2022 |
| Public Announcement (NASDAQ: IXHL) (ASX: IHL) |
Melissa Kostopoulos
ASX
Listings Compliance adviser
ASX Limited
Level 4, North Tower, Rialto
525 Collins Street
Melbourne VIC 3000
| By email: | Melissa.Kostopoulos@asx.com.au | |
| tradinghaltsmelbourne@asx.com.au |
Dear Melissa,
REQUEST FOR TRADING HALT – INCANNEX HEALTHCARE LIMITED
Incannex Healthcare Limited (‘Company’) requests a trading halt to be applied to its securities under ASX Listing Rule 17.1 pending an announcement by the Company regarding a strategic institutional capital raising.
The Company requests that the trading halt commences immediately. The Company requests that the trading halt remains in place until the earlier of the commencement of normal trading on 05th December 2022 or the release of the announcement.
The Company confirms that it is not aware of any reason why the trading halt should not be granted or of any information other than that set out above necessary to inform the market about the trading halt.
For and on behalf of the Board of Incannex Healthcare Limited.
Regards,
Madhukar
Bhalla
Company Secretary
Incannex Healthcare Limited (ABN: 93 096 635 246)
Level 39, Rialto South Tower, 525 Collins Street, Melbourne VIC
3000 P: +61 (0) 409 840 786
Page 1 | 1